Target-controlled infusion (TCI) | Manual infusion (MI) | ||
---|---|---|---|
(N = 20) | (N = 20) | P | |
Male/Female | 6/12 | 12/6 | 0.11 |
Age, yr, mean ± SD | 38.1 ± 13.8 | 40.0 ± 11.8 | 0.60 |
Weight, kg, mean ± SD | 63.5 ± 16.7 | 70.9 ± 15.1 | 0.15 |
Height, cm, mean ± SD | 160.8 ± 8.0 | 164.7 ± 9.8 | 0.18 |
BMI, kg/m2, mean ± SD | 24.4 ± 5.5 | 26.3 ± 5.4 | 0.29 |
ECT factors | |||
Total number of ECT treatments, mean ± SD | 7.2 ± 3.2 | 7.6 ± 2.8 | 0.68 |
Seizure threshold, mC, mean ± SD | 100.0 ± 31.1 | 96.8 ± 50.5 | 0.81 |
Stimulus dose of the last treatment, mC, mean ± SD | 306.7 ± 176.2 | 251.6 ± 136.1 | 0.30 |
Seizure adequacy, %, mean ± SD | 48.0 ± 28.7 | 45.2 ± 28.6 | 0.40 |
Anesthesia-related factors | |||
ASA class 1–2/ASA class 3 | 16/4 | 18/2 | 0.66 |
Predicted blood level of propofol, μg/mL, mean ± SD | 3.16 ± 0.86 | 2.71 ± 0.78 | < 0.001 |
Total dose of propofol, mg/kg, mean ± SD | 1.31 ± 0.60 | 1.06 ± 0.22 | < 0.001 |
Succinylcholine, mg/kg, mean ± SD | 1.10 ± 0.30 | 1.20 ± 0.28 | 0.002 |
ASTI, min, mean ± SD | 4.55 ± 1.68 | 3.63 ± 1.29 | < 0.001 |
Recovery time, min, mean ± SD | 7.98 ± 8.83 | 5.84 ± 4.76 | 0.015 |
Diagnosis, N (%) | |||
Schizophrenia | 8 (40%) | 8 (40%) | 1 |
Bipolar disorder | 5 (25%) | 7 (35%) | 0.49 |
Major depressive disorder | 7 (35%) | 5 (25%) | 0.49 |
Psychotropic medication, N (%) | |||
Antipsychotics | 17 (85%) | 15 (75%) | 0.70 |
Antidepressants | 9 (45%) | 8 (40%) | 0.75 |
Benzodiazepines | 8 (40%) | 8 (40%) | 1 |
Clinical scales, baseline, mean ± SD | |||
CGI-S | 5.39 ± 0.92 | 5.22 ± 0.73 | 0.55 |
CGI-I | 4.78 ± 0.88 | 4.78 ± 0.94 | 1 |
MoCA | 18.2 ± 9.7 | 20.2 ± 8.6 | 0.52 |